Renal denervation offers new hope for patients with uncontrolled hypertension (high blood pressure)
India Medtronic Private Limited, a subsidiary of Medtronic plc, has announced the launch of the Symplicity™ Spyral renal denervation system (RDN) for treating high blood pressure. The RDN is a minimally invasive therapy that targets overactive nerves near the kidneys, which can lead to high blood pressure. This launch follows the recent approval of the system by the US Food and Drug Administration and the Indian regulatory authorities.
In India, nearly 1 in 4 adults have hypertension, which is a significant risk factor for cardiovascular death. It increases the chances of heart attack, stroke, heart failure, and kidney failure. Despite its serious implications, hypertension often goes undiagnosed due to the lack of symptoms. Raising awareness about this condition is crucial, as it is detectable, preventable, and treatable.
The Symplicity Spyral blood pressure procedure has demonstrated clinical efficacy in reducing high blood pressure and lowering health risks. This minimally invasive procedure targets the nerves near the kidneys that contribute to elevated blood pressure. After sedation, a small incision is made and a thin tube, called a catheter, is inserted into the artery leading to the kidney. The doctor then uses the catheter to calm the overactive nerves, before removing the tube without leaving any implant behind.
Michael Blackwell, Vice President and Managing Director of Medtronic India, expressed their goal of empowering healthcare professionals and offering a comprehensive approach to managing uncontrolled hypertension with the Symplicity blood pressure procedure. The recent FDA approval and the endorsement by the European Hypertension Society highlight the role of RDN in hypertension care. Medtronic aims to provide this therapy to all eligible patients in India, furthering their commitment to improving patients’ lives through innovative cardiovascular therapies.
The Medtronic RDN program has extensive experience, with over 25,000 patients globally. It has been studied in various patient groups, including those with comorbidities or high baseline cardiovascular risk. The procedure has consistently shown significant and sustained reductions in blood pressure among patients with uncontrolled hypertension, with minimal adverse events.
Hypertension, often referred to as the silent killer, is characterized by abnormally high blood pressure. While it may not exhibit warning signs or symptoms, some people report early morning headaches, nosebleeds, irregular heart rhythms, and buzzing in the ears. Hypertension significantly increases the risk of heart, brain, kidney, and other diseases, and is a major cause of premature death. Individuals experiencing high or difficult to control blood pressure are encouraged to consult with their doctors to learn more about the Symplicity procedure.
Medtronic plc is a global healthcare technology company headquartered in Dublin, Ireland, focused on finding solutions to the most challenging health problems facing humanity. With a mission to alleviate pain, restore health, and extend life, Medtronic delivers innovative technologies and therapies across multiple health conditions, including cardiac devices, surgical robotics, insulin pumps, and patient monitoring systems.
The launch of the Symplicity™ Spyral renal denervation system by India Medtronic Private Limited marks a significant advancement in the management of uncontrolled hypertension. By targeting the overactive nerves near the kidneys, this minimally invasive procedure offers new hope to patients by reducing high blood pressure and mitigating serious health risks associated with hypertension. With its commitment to improving patients’ lives, Medtronic continues to lead in cardiovascular therapies and provide innovative solutions for a better future.
